Division of Cancer Treatment and Diagnosis, Room 3A-44, Building 31, 31 Center Drive, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
- James H. Doroshow &
- Shivaani Kummar
Developmental Therapeutics Branch of the Center for Cancer Research, Room 3A-44, Building 31, 31 Center Drive, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
- James H. Doroshow
Both authors contributed substantially to all stages of the preparation of this manuscript.
Competing interests statement
The authors declare no competing interests.
James H. Doroshow
Dr James H. Doroshow has been the Deputy Director for Clinical and Translational Research of the National Cancer Institute since 2011, and the Director of NCI's Division of Cancer Treatment and Diagnosis since 2004. He continues to pursue his own research programme as a Senior Investigator in the Developmental Therapeutics Branch of the NCI's intramural Center for Cancer Research. He is the author of over 400 full-length publications in the areas of molecular pharmacology, the role of oxidant stress in tumour cell signal transduction, and novel therapeutic approaches to solid tumours. He is currently a member of the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine of the National Academies of Science and the Associate Editor for Oncology of the 25th Edition of the Cecil Textbook of Medicine.
Dr Shivaani Kummar is Head of Early Clinical Trials Development in the office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI). Upon completion of her fellowship training in Medical Oncology and Hematology from the National Institutes of Health, Bethesda, MD, she joined the Yale Cancer Center, Yale University, New Haven, Connecticut as an Assistant Professor in Medical Oncology. She moved back to the NCI in 2004 and heads the Developmental Therapeutics Clinical program at the NCI. She serves on a number of scientific committees, including the track leadership for the Developmental Therapeutics - Experimental Therapeutics Track, Scientific Program Committee of the American Society of Clinical Oncology 2013–2014. Her research focuses on the clinical development of novel cancer therapeutics and she has published extensively in peer-reviewed journals.